Centiva Capital’s Lucid Diagnostics LUCD Stock Holding History

Centiva Capital’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$79.4K	Buy	+69,063	New	+$87.9K	﹤0.01%	1428
2025 Q4	–	Sell	-24,949	Closed	-$25.2K	–	1470
2025 Q3	$25.2K	Buy	+24,949	New	+$27.2K	﹤0.01%	978

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Centiva Capital's LUCD Position: Q1 2026 in Review

Centiva Capital opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 69,063 shares worth $79.4K. The stake represents ﹤0.01% of the portfolio and ranks #1428 among its holdings. This is a return to the name: Centiva Capital previously reported a position in LUCD as recently as Q3 2025.

Centiva Capital first reported a position in LUCD in Q3 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Centiva Capital held 69,063 shares of Lucid Diagnostics worth $79.4K as of Q1 2026.
Lucid Diagnostics was a new Centiva Capital position in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1428 holding.
Centiva Capital first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 2 quarters since.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.